For the Inventor, By the Inventor

Enter assignee name

Geneva, Switzerland

Novimmune Sa

Calculating rank

USPTO Granted Patents = 65

% Expired Patents = 10.8

CIPO Patents = 8

EPO Patents = 23

Trademarks = 3

Forward Citations = 409

Loading Chart...

Loading Chart...

54 inventors (with patents filed for the assignee):

Greg Elson (35 out of 36 patents)

Nicolas Fischer (31 out of 32 patents)

Olivier Leger (26 out of 28 patents)

4. Marie Kosco-Vilbois (24 out of 30 patents)

5. Krzysztof Masternak (14 out of 15 patents)

6. Giovanni Magistrelli (11 out of 11 patents)

7. Francois Rousseau (10 out of 11 patents)

8. Walter Ferlin (9 out of 9 patents)

9. Franck Gueneau (6 out of 6 patents)

10. Ulla Ravn (6 out of 6 patents)

11. Florence Guilhot (6 out of 6 patents)

12. Bernard Francois Mach (6 out of 9 patents)

13. Pauline Malinge (4 out of 4 patents)

14. Yann Dean (4 out of 6 patents)

15. Limin Shang (4 out of 4 patents)

Core Competencies:

Bispecific Antibodies

Anti-CD47

PD-L1

IL-6

Multispecific

Antibody Drug Conjugates

Neutralizing Antibodies

Autoimmune Diseases

TLR4

Chimeric Polypeptides

Therapeutic Methods

Polypeptide Libraries

65 patents: Sort by Forward Citations

1. 12583922 - BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF (2026-03-24),

2. 12448444 - Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof (2025-10-21),

3. 11840553 - Anti-CD47 antibodies and methods of use thereof (2023-12-12),

4. 11827703 - Compositions and methods related to anti-CD19 antibody drug conjugates (2023-11-28),

5. 11613582 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2023-03-28),

6. 11401299 - Generating multispecific antibody mixtures and methods of uses thereof (2022-08-02),

7. 11261262 - Readily isolated bispecific binding molecules with native format having mutated constant regions (2022-03-01),

8. 11260117 - Anti-CD47 x anti-mesothelin antibodies and methods of use thereof (2022-03-01),

9. 11203646 - Anti-CD3 epsilon antibodies and methods of use thereof (2021-12-21),

10. 11059910 - Anti-CD47 antibodies and methods of use thereof (2021-07-13),

11. 10982004 - Anti-TLR4 antibodies and uses thereof (2021-04-20),

12. 10844132 - Neutralizing antibodies and methods of use thereof (2020-11-24),

13. 10759862 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2020-09-01),

14. 10759858 - Anti-CD3 antibodies and methods of use thereof (2020-09-01),

15. 10689461 - Antibody dual display dual compositions and methods of use thereof (2020-06-23),

Company Overview

Novimmune SA, based in Geneva, Switzerland, specializes in the development of innovative bispecific antibodies aimed at treating various diseases, including autoimmune disorders and cancers. The company focuses on advanced therapeutic modalities such as anti-CD47, PD-L1, and IL-6, as well as multispecific and antibody-drug conjugate technologies. By leveraging its expertise in neutralizing antibodies, Novimmune aims to create effective treatment options that address unmet medical needs in challenging therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

65 Patents

#10 in Geneva

#250 in Switzerland

#11,339 in the World

Geneva, Switzerland

Novimmune Sa

Forward Citations = 409

54 inventors:

Greg Elson (35 out of 36 patents)

Nicolas Fischer (31 out of 32 patents)

Olivier Leger (26 out of 28 patents)

4. Marie Kosco-Vilbois (24 out of 30 patents)

5. Krzysztof Masternak (14 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novimmune Sa. Retrieved from https://idiyas.com/company/novimmune-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…